Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?

dc.contributor.author	Mihály, Zsuzsanna
dc.contributor.author	Panajotu, Alexisz
dc.contributor.author	Győrffy, Balázs
dc.date.accessioned	2017-01-12T13:49:50Z
dc.date.available	2017-01-12T13:49:50Z
dc.date.issued	2012
dc.identifier	84901193258
dc.identifier.citation	pagination=192-193; journalVolume=1; journalIssueNumber=3; journalTitle=TRANSLATIONAL ANDROLOGY AND UROLOGY;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/3921
dc.identifier.uri	doi:10.3978/j.issn.2223-4683.2012.06.07
dc.relation.ispartof	urn:issn:2223-4683
dc.title	Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
dc.type	Journal Article
dc.date.updated	2016-12-09T10:39:07Z
dc.language.rfc3066	en
dc.identifier.mtmt	2115302
dc.contributor.department	SE/AOK/K/I. Sz. Gyermekgyógyászati Klinika
dc.contributor.department	SE/AOK/K/ISZGYK/MTA-SE Gyermekgyógyászati és Nephrológiai Kutatócsoport
dc.contributor.institution	Semmelweis Egyetem